What is the Tetramethylpyrazine?

Tetramethylpyrazine is white crystals or powder, while it's Molecular Formula is C8H12N2. white crystals or powder Usually used in research and treatment of multiple disorders.

What is the CAS number for Tetramethylpyrazine?

The CAS number of Tetramethylpyrazine is 1124-11-4.

What is Tetramethylpyrazine (1124-11-4) used for?

2,3,5,6-Tetramethylpyrazine is an alkaloid that has been found in L. wallichii and has diverse biological activities. It reduces kainate-induced increases in production of reactive oxygen species (ROS) and cytotoxicity in primary rat hippocampal neurons when used at a concentration of 5 μM. 2,3,5,6-Tetramethylpyrazine (0.1 mM) induces vasodilation in precontracted isolated and endothelium-denuded rat tail artery strips and reduces blood pressure in anesthetized rats. It decreases infarct volume, caspase-3 activation, and hypoxia-inducible factor-1α (HIF-1α) levels in a rat model of focal cerebral ischemia induced by middle cerebral artery occlusion (MCAO) when administered at a dose of 20 mg/kg.InChI:InChI=1/C8H12N2/c1-5-6(2)10-8(4)7(3)9-5/h1-4H3

What is the Tetramethylpyrazine?

Tetramethylpyrazine is white crystals or powder, while it's Molecular Formula is C8H12N2. white crystals or powder Usually used in research and treatment of multiple disorders.

What is the CAS number for Tetramethylpyrazine?

The CAS number of Tetramethylpyrazine is 1124-11-4.

What is Tetramethylpyrazine (1124-11-4) used for?

2,3,5,6-Tetramethylpyrazine is an alkaloid that has been found in L. wallichii and has diverse biological activities. It reduces kainate-induced increases in production of reactive oxygen species (ROS) and cytotoxicity in primary rat hippocampal neurons when used at a concentration of 5 μM. 2,3,5,6-Tetramethylpyrazine (0.1 mM) induces vasodilation in precontracted isolated and endothelium-denuded rat tail artery strips and reduces blood pressure in anesthetized rats. It decreases infarct volume, caspase-3 activation, and hypoxia-inducible factor-1α (HIF-1α) levels in a rat model of focal cerebral ischemia induced by middle cerebral artery occlusion (MCAO) when administered at a dose of 20 mg/kg.InChI:InChI=1/C8H12N2/c1-5-6(2)10-8(4)7(3)9-5/h1-4H3

Product classification

1124-11-4

Product Name：Tetramethylpyrazine
Molecular Formula：C₈H₁₂N₂
Purity：99%
Molecular Weight：136.197

Inquiry

Product Details;

CasNo： 1124-11-4

Molecular Formula： C₈H₁₂N₂

Appearance： white crystals or powder

Manufacturer supply top purity Tetramethylpyrazine 1124-11-4 with ISO standards

Molecular Formula:C8H12N2
Molecular Weight:136.197
Appearance/Colour:white crystals or powder
Vapor Pressure:0.671mmHg at 25°C
Melting Point:82-86 °C
Refractive Index:1.503
Boiling Point:192.7 °C at 760 mmHg
PKA:3.20±0.10(Predicted)
Flash Point:71.6 °C
PSA：25.78000
Density:1.08 g/cm³
LogP:1.71020

Tetramethylpyrazine(Cas 1124-11-4) Usage

Chemical Characteristic	White crystal or powder. With aroma of beef and heated lard and fermented soybean flavor. It smells chocolate flavor when diluted to 20mg/kg. Boiling point is 190℃. Melting point is between 84 and 86℃. Soluble in ethanol, most non-volatile oils and propylene glycol, slightly soluble in water. Natural products exist in guava, roast beef, cocoa, coffee, shrimp and so on.
Preparation	Butanedione monoxime generated by butanone and ethyl nitrite condensation is reduced and cyclized to produce methylpyrazine. The cyclization reaction product is subjected to steam distillation and the distillate is cooled,crystallized and filtered to generate crude tetramethylpyrazine which is refined with water recrystallization and activated carbon to decolor. Ethanol solution with 15% to 20% hydrogen chloride can be added into acetone to prepare hydrochloride salt. Condensed by 2,3-butanedione and 2,3-butanediamine.
History	Ligusticum walliichi has a long medicinal history in China and is used in the treatment of headache, promoting blood and Qi circulation, curing chills and alleviating pain”. Clinically, it is mainly used for the treatment of cardiovascular and cerebrovascular diseases. Ligustrazine (2,3,5,6-tetramethylpyrazine) is the main active ingredient of Ligusticum walliich. It was first isolated in 1962 .In recent years, studies have found that ligustrazine can inhibit the activity of the cerebral cortex and medullary respiratory center, excite vasomotors, induce the expansion of peripheral blood vessels, promote the blood flow of the coronary artery and lower limbs, and reduce blood pressure. Ligustrazine can also paralyze the nerve center and has sedative and analgesic effects.Studies have suggested that ligustrazine has a variety of new effects, including improving leptomeningeal and peripheral microcirculation and increasing cerebral blood flow, and its effect is better than that of papaverine. Ligustrazine can also protect against experimental cerebral ischemia and alleviate brain edema and the deposition of fibrin in microvessels. Ligustrazine is also used in the treatment of pulmonary heart disease, heart failure, dilated heart disease, portal hypertension, type II diabetes mellitus, tumor and coronary heart disease, and restenosis after stent implantation .
Indications	Ligustrazine is used for occlusive vascular diseases, cerebral thrombosis, vasculitis, coronary heart disease, angina pectoris, and others
Pharmacology	Traditional Chinese medicine has some advantages in comprehensive treatment under multisite, multitarget conditions and overall regulation. Ligustrazine can inhibit phosphodiesterase activity and inhibit platelet aggregation. It has the typical characteristics of a calcium antagonist and can adjust the release of various vasoactive substances against the vasoconstrictive action of the sympathetic nerve, improve microcirculation, reduce red blood cell aggregation, shorten the erythrocyte electrophoresis time, and thereby reduce blood viscosity .Ligustrazine can inhibit the proliferation of vascular endothelial cells induced by vascular endothelial growth factor, which may be one of the mechanisms by which angiogenesis is inhibited. The mechanism by which ligustrazine inhibits the proliferation of vascular endothelial cells may be through calcium ion retardation, inhibition of cell adhesion molecules, or through the antagonistic or synergistic effects of some growth factors involved in the proliferation and angiogenesis of vascular endothelial cellsStudies have shown that ligustrazine plays a role in resistance to ischemiareperfusion injury and antiapoptotic effects via the phosphatidylinositol 3- kinase/ protein kinase B (PI3K/Akt) pathway. The phosphorylation of endothelial nitric oxide synthase (eNOS) and generation of nitric oxide (NO) are important downstream effectors, which significantly enhance the myocardial protective effects of ligustrazine. one of the mechanisms of resistance to fibrosis .
Safety Profile	Poison by intravenous and intraperitoneal routes. Moderately toxic by ingestion. When heated to decomposition it emits toxic fumes of NOx.
Physical properties	Appearance: colorless needle crystal. Solubility: soluble in hot water, petroleum ether, chloroform, dilute hydrochloric acid, slightly soluble in ether, insoluble in cold water. Melting point: 77–80°C. Boiling point: 190°C. Flash point: 128– 130°C/200mm. Ligustrazine has a particular odor, moisture absorption, and sublimation.
Definition	ChEBI: A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum wallichii).
Aroma threshold values	Detection: 1 to 10 ppm. Aroma characteristics at 1.0%: slightly musty, nutty, cocoa-like with a vanilla undernote
Taste threshold values	Taste characteristics at 10 ppm: weak, nutty, musty cocoa and chocolate-like with dry coffee nuances.
General Description	2,3,5,6-Tetramethylpyrazine has been isolated from Ephedra sinica. It is useful in the treatment of several disorders such as asthma, heart failure, rhinitis and urinary incontinence. It is a flavor ingredient of tobacco. It forms cocrystal with 4-hydroxybenzoic acid which exhibits supramolecular synthon polymorphism.